TrialThe New England journal of medicine2015
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Marc S Sabatine et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
585 papers cite itlatest 60 shown
this paperpooled ittrialcites it